Search Results 1141-1150 of 19028 for Neutrophil

1. Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma - Mayo Clinic

   Hematology: Absolute neutrophil count (ANC) >1,500 cells/mm3, platelet count >100,000 cells/ mm.cu. and hemoglobin > 9 g/dL;; Hepatic: bilirubin <1.5 X Upper ...

2. A Study to Evaluate Combination Therapy to Treat Newly-diagnosed Diffuse Anaplastic Wilms Tumors and Relapsed Favorable Histology Wilms Tumors A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT - Mayo Clinic

   Peripheral absolute neutrophil count (ANC) ≥ 750/uL (performed within 7 days prior to enrollment). Platelet count ≥ 75,000/uL (transfusion independent) ...

3. Study Of Lurbinectedin In Combination With Doxorubicin Versus Doxorubicin Alone As First-line Treatment In Participants With Metastatic Leiomyosarcoma - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL (patients may have received prior red blood cell [RBC] transfusion); absolute neutrophil count (ANC) ≥ 2.0 x 10^9 /L, and platelet ...

4. Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma - Mayo Clinic

   Absolute neutrophil count (ANC) > 1,500 cells/μl without the use of hematopoietic growth factors within last 7 days prior to Screening;; Platelet count ...

5. Erismodegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma - Mayo Clinic

   Contact the study team to discuss study eligibility and potential participation. Show more eligibility criteria. Inclusion Criteria: Absolute neutrophil count ...

6. A Study of Lenalidomide Combined with a Standard Chemotherapy for Treating Patients with Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma - Mayo Clinic

   Absolute neutrophil count (ANC) > 1000 cells/mm^3. Unless cytopenic due to non-Hodgkin lymphoma bone marrow involvement or splenomegaly. Platelet count > 100 ...

7. Lurbinectedin + Doxorubicin In Leiomyosarcoma - Mayo Clinic

   Participation eligibility · Absolute Neutrophil Count ≥ 1,500/mcL; · Hemoglobin (Hgb) ≥ 8 g/dl (transfusion support permitted); · Platelet Count ≥ 100,000/mcL; ...

8. A Study to Evaluate Genetic Testing in Guiding Treatment for Patients with Brain Metastases - Mayo Clinic

   - Absolute neutrophil count (ANC) ≥ 1,500/mm^3. Platelet count ≥ 100,000/mm^3. Total bilirubin ≤ 1.5 x upper limit of normal (ULN) except in patients ...

9. A Phase 3, randomized, open-label, controlled study comparing the efficacy and safety of zanidatamab to trastuzumab, each in combination with physician’s choice chemotherapy, for the treatment of participants with metastatic HER2-positive breast cancer - Mayo Clinic

   Absolute neutrophil count ≥ 1000/mm . Platelet count ≥ 100,000/mm ; participants with stable platelet count from 75,000 to 100,000/mm may be included with ...

10. A Study Of Home-Based Therapy For Glioma - Mayo Clinic

    Absolute neutrophil count (ANC) ≥ 1,500. Platelet count ≥ 100,000 at baseline prior to systemic therapy initiation. Alanine aminotransferase (ALT) and ...